The Editors’ Choice
The results of this study need to be accounted for when defining reference doses for food labeling and when advising patients about the effect of cofactors.A topical Janus kinase inhibitor in pediatric patients with atopic dermatitis Novel topical treatment options are still needed for pediatric pat...
Saved in:
Published in | Journal of allergy and clinical immunology Vol. 144; no. 6; p. 1509 |
---|---|
Format | Journal Article |
Language | English |
Published |
St. Louis
Elsevier Limited
01.12.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 0091-6749 1097-6825 |
DOI | 10.1016/j.jaci.2019.10.025 |
Cover
Summary: | The results of this study need to be accounted for when defining reference doses for food labeling and when advising patients about the effect of cofactors.A topical Janus kinase inhibitor in pediatric patients with atopic dermatitis Novel topical treatment options are still needed for pediatric patients with atopic dermatitis (AD). In this issue, Grossman et al (p 1524) analyzed longitudinal data on exacerbations in 1840 subjects (24% self-reported black) with mild-to-moderate asthma from 12 National Institutes of Health/National Heart, Lung, and Blood Institute–sponsored clinical trial cohorts, including a subset with genome-wide genetic data to estimate global percentage of African ancestry. Because the interferon response of sinonasal epithelial cells, which is critical for defense against viral infection, remains unknown, Hwang et al (p 1551) examined the expression levels of type I and III interferons and interferon-stimulated genes (ISGs) in patients with chronic rhinosinusitis. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
ISSN: | 0091-6749 1097-6825 |
DOI: | 10.1016/j.jaci.2019.10.025 |